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Abstract: The successful completion of the Human Genome Project (HGP) was an 
unprecedented scientific advance that has become an invaluable resource in the search for 
genes that cause monogenic and common (polygenic) diseases. Prior to the HGP, linkage 
analysis had successfully mapped many disease genes for monogenic disorders; however, 
the limitations of this approach were particularly evident for identifying causative genes in 
rare genetic disorders affecting lifespan and/or reproductive fitness, such as skeletal dysplasias. 
In this review, we illustrate the challenges of mapping disease genes in such conditions 
through the ultra-rare disorder fibrodysplasia ossificans progressiva (FOP) and we discuss 
the advances that are being made through current massively parallel (“next generation”) 
sequencing (MPS) technologies.
Keywords: Human Genome Project; fibrodysplasia ossificans progressiva; monogenic 
diseases; disease gene discovery; NGS 
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1. Introduction 
Until very recently, mapping the causative gene for monogenic diseases depended on finding 
families with demonstrable Mendelian inheritance of the disease, preferably in multiple generations. 
Linkage approaches in such families were successful in identifying mutations responsible for many of 
the more frequent monogenic diseases and traits [1]. However, identifying the underlying mutations in 
rare genetic diseases, especially those associated with low reproductive fitness, late onset diseases, or 
diseases with early lethality, proved much more challenging. 
The Human Genome Project (HGP) set the stage for success in meeting these challenges. The ultra-rare 
disorder fibrodysplasia ossificans progressiva (FOP), with a frequency of one in two million, is an 
example of such a success. Linkage in FOP families identified chromosomal regions of interest; 
Human Genome Project databases then facilitated the identification of candidate genes within the 
linkage region and permitted the efficient identification of altered DNA sequences. FOP was found  
to be caused by a recurrent single nucleotide substitution occurring in >95% of patients. Despite  
the ultimate success in mapping the FOP gene, this discovery took decades of effort to identify  
families with inheritance of the disease (linkage analysis was eventually accomplished with just five 
two-generation families) followed by the time-consuming tasks of conducting genome-wide linkage 
analysis, and subsequent identification and re-sequencing of candidate genes within the linkage 
intervals. Knowing the genetic mutation in FOP has led quickly to better understanding of the 
underlying pathology and directed strategies for treatments, neither of which were possible before 
molecular aetiology was determined. 
Building on the technology, computation, and scientific information generated through the HGP, 
the continued advances in mapping disease genes have been extraordinarily rapid. Faced today with 
the challenge of identifying a rare gene mutation in a disease like FOP, high-throughput exome and/or 
whole genome sequencing approaches would identify the genetic mutation rapidly. Moreover, gene 
identification may require sequencing of only a small number of unrelated cases, small families, or,  
in some cases, even a single proband. These breakthroughs are leading to an upsurge in disease gene 
discoveries with their associated benefits [2]. 
After mapping a disease-causing gene, many challenges remain in understanding additional genetic 
contributions to disease onset and progression. In FOP, for example, although the main disease 
characteristics are unique and readily recognized there is significant variability in the age of disease 
onset, the rate of disease progression, and the severity of disease, likely to arise from as yet un-identified 
genetic causes. Similar issues exist with many common heritable diseases such as osteogenesis 
imperfecta and Marfan’s syndrome. With further development of genome technologies, the ability to 
understand phenotypic variability and the participation of genetic modifiers is becoming a reality. 
2. Linkage Mapping 
2.1. History of Linkage Mapping 
At the turn of the twentieth century, Archibald Garrod coined the term “inborn errors of metabolism” 
to explain the increased incidence of alkaptonuria (and, subsequently, also cystinuria, pentosuria, and 
albinism) in consanguineous families compared with the general population, and suggested that these 
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conditions were caused by transmissible elements within families [3]. Since this time, the challenge 
has been to identify these errors. 
For most of the twentieth century, linkage mapping was the standard means of identifying the 
gene/s underlying an inherited disorder. Linkage is the co-segregation of a genetic region with disease 
phenotype within a family. Markers, such as restriction fragment length polymorphisms, microsatellites, 
or single nucleotide polymorphisms (SNPs), are genotyped in family members. Markers close to  
a disease-causing mutation will be co-inherited with the disease-causing mutation, unless separated by 
a meiotic event—the closer the marker to the disease-causing gene, the less likely it will be separated 
at meiosis. An area of linkage within a family may thus extend a considerable genetic distance. Whole 
genome linkage scans, in which approximately 300–400 microsatellite markers are genotyped in 
family members, usually result in identification of regions of linkage spanning 10–20 cM (on average 
~10–20 million DNA bases). Such a region may harbor many hundreds of genes, and fine mapping (by 
further marker genotyping and/or sequencing of candidate genes) will usually be necessary to identify 
the exact causative gene. 
2.2. Weaknesses of the Linkage Approach 
Traditional “parametric” linkage analysis compares the likelihood of the observed transmission of 
genetic markers in relation to the trait or disease, in the context of a specified model of inheritance. 
Non-parametric methods not requiring knowledge of mode of inheritance can be used, though are less 
powerful when the correct mode of inheritance is known. Diseases with late onset of clinical features 
or with incomplete penetrance are harder to map by linkage due to possible incorrect attribution of 
disease status among family members. Diseases with significant gene/environment interaction present 
similar issues, unless all family members are exposed to the same environmental stressors. The ability 
to map a gene also depends on the number of informative meioses within a pedigree. Thus, large 
families with many affected individuals—especially distantly-related individuals who will have a high 
number of meioses and recombination events between them—are the most useful for linkage mapping. 
Diseases that affect reproductive fitness (such as skeletal dysplasias) are less likely to have such large 
informative pedigrees. One solution to this problem is to use many families affected by the same 
condition in order to identify a common linkage region shared by affected persons within each family. 
This strategy requires that the disease be caused by mutations in the same single common locus in all 
families, although the causative mutation within this common locus may be unique in each individual 
family. The approach will, therefore, not be successful for diseases with “phenocopies”, in which  
a clinical phenotype may arise from mutations in more than one gene. (For example, phenocopies 
might result if mutations in various genes along a biological pathway resulted in a common phenotypic 
endpoint.) “Pooling” linkage information from families with disparate underlying causes would not be 
a successful strategy. Extremely rare diseases are, by definition, extremely rare; obtaining sufficient 
number of families to pool their linkage information will usually require international collaboration. 
Lastly, novel/spontaneous mutations (those newly occurring within an individual) cannot be mapped 
by linkage. 
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2.3. Successes in Linkage Mapping: Monogenic vs. Complex Diseases 
Despite these limitations, mapping monogenic diseases by linkage has been quite successful, even 
for rare diseases, with well over 1000 monogenic (Mendelian) disorders mapped by the turn of  
the century [1]. Approximately two-thirds of the 400 or so recognized skeletal dysplasias were mapped 
by linkage or similar approaches by 2010 [4]. In contrast, mapping complex diseases by linkage was 
much less successful. Complex genetic diseases are typically polygenic in nature: affected individuals 
have different variants in multiple, but overlapping, sets of genes, with each variant contributing only  
a small part to the final overall phenotype. Before the era of high throughput microarray genotyping 
and the advent of genome-wide association studies (GWAS), only a handful of genes had been 
identified for complex diseases using linkage [5]. 
3. Mapping the FOP Gene Highlights the Challenges 
Fibrodysplasia ossificans progressiva (FOP; MIM 135100) is a severe disorder of progressive  
and extensive extra-skeletal ossification. Heterotopic ossification in FOP begins in childhood within 
connective tissues, such as skeletal muscle, tendon, and ligament. Onset of bone formation can be 
induced by trauma, or may occur spontaneously. Bone formation is episodic, leading to cumulative 
disability and shortened lifespan [6]. 
Reproductive fitness is low in FOP, resulting in infrequent inheritance and a population frequency 
(about one per two million) that reflects the rate of new mutations. When the search for the FOP gene 
began, only very few cases of familial inheritance of FOP had been reported, with most known cases 
occurring de novo in families (reviewed in [7,8]). Although these few family pedigrees suggested an 
autosomal dominant mode of inheritance, the paucity of families with transmission of FOP made 
genome-wide linkage analysis, the state-of-the-art approach at the time, an impractical strategy for 
gene identification. 
Eventually, four small pedigrees with autosomal dominant inheritance of FOP were identified, 
although some had ambiguous clinical features. An initial genome-wide linkage analysis using  
240 microsatellite markers (spaced  25 cM) was conducted, although it was recognized that there  
was incomplete/uneven marker coverage across the genome and many markers lacked sufficient 
informativity [9]. Whilst the initial linkage analysis focused attention on a chromosome 4 locus [9], 
further analysis revealed additional linked loci on chromosomes 2 and 6. However, subsequent 
sequencing analysis of numerous candidate genes in the linkage regions revealed no identifiable 
mutations. The limited information available at this time about the human genome, including gene 
locations and sequence, made this process much more challenging. 
As genome analysis technologies continued to develop and additional families with autosomal 
dominant transmission of FOP were identified, further genome-wide linkage studies were performed. 
These used both a higher density SNP marker panel as well as more dense and informative 
microsatellite panels, which were combined in a single analysis. The international team involved 
focused their studies on five two-generation families with stringent and unambiguous phenotypic 
features of FOP in all affected family members (congenital malformation of the great toes and 
progressive heterotopic ossification in characteristic anatomic patterns). Consistent linkage was then 
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demonstrated with the chromosome 2q23–24 interval in all five families (LOD score 2.3) [8], with no 
other locus segregating with the disease in all pedigrees. Using better characterized and annotated 
human DNA sequences generated through the Human Genome Project (HGP), we selected candidate 
genes within the 16.5 Mb linkage interval for sequencing and mutation identification. The interval 
contained more than 40 known genes, however, concurrent investigations had identified the BMP 
signaling pathway as altered in FOP [10–13], and genes in this pathway were given high priority.  
One such gene was the Activin A type I receptor gene (ACVR1; OMIM 102576; also known as Alk2 or 
ActRI), encoding a receptor for bone morphogenetic protein (BMP). 
DNA sequence analysis of all ACVR1 protein-coding exons and splice junctions identified a 
heterozygous c.617G>A (Arg206His; CGC  CAC) mutation present in all affected members in these 
FOP families, with the same mutation present in multiple sporadic cases of FOP [8]. 
Cumulative data over the past eight years shows that FOP is caused by this recurrent single 
nucleotide substitution in >95% of patients ([14–16]). In exceptional cases of FOP, mainly those 
whose phenotype varies slightly from the description above, affected individuals have mutations at 
other amino acid positions in ACVR1 in the glycine-serine (GS) or protein kinase domains [14,17]. 
Thus far, all patients clinically diagnosed with the “classical” FOP phenotype have ACVR1 mutations, 
and these mutations are fully penetrant. 
4. Massive Parallel Sequencing: A New Era 
The mapping of rare monogenic disorders has been completely transformed by the advent of 
massive parallel sequencing (MPS), also known as “next-generation” sequencing. In the last few years, 
the causative genes for dozens of monogenic disorders have been identified using MPS, and the rate of 
discovery has been exponential. To illustrate this latter point, we recently published a review of MPS 
in skeletal dysplasias; at the time of paper submission (April 2013) 26 papers had been published using 
MPS to identify the causative gene for 22 skeletal dysplasias; by the time of paper acceptance  
(July 2013) a further ten papers had added another six novel skeletal dysplasia genes to the list [2]. 
Since then, further causative genes for skeletal dysplasias, as well as a host of other Mendelian disorders, 
have been identified, and it is likely that many of the remaining unmapped monogenic diseases will 
prove tractable to mapping by MPS. 
4.1. MPS Technologies 
Disease gene identification by MPS became possible because of three main developments: the 
technology of sequencing multiple genetic regions simultaneously; the success of the Human Genome 
Project in providing a complete and reliable reference genome for comparison with the test sequence 
data; and the availability of large databases of genomic information from healthy individuals, and 
increasingly in patients with disease, to assist in assessment of variants observed. 
The pivotal technological breakthrough for MPS was the development of technologies and 
platforms for simultaneous sequencing of multiple regions of fragmented DNA or RNA in a single 
experiment. It is beyond the scope of this paper to provide a comprehensive discussion of these 
technologies. However, briefly: DNA is fragmented and common adapters are ligated to the fragment 
ends. The fragments are subsequently amplified by PCR, followed by sequencing-by-synthesis, the 
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common adapters providing uniform starting templates for both the amplification and sequencing 
reactions for all fragments (more recent technological developments, so-called “third-generation” 
technologies, involve sequencing without this step of any preceding amplification, improving both 
accuracy and speed of MPS). Sequencing-by-synthesis involves addition of bases to a growing strand: 
as each base is added, a signal is generated and “read” by the software, thus generating the sequence of 
each fragment. The sequence of each fragment is then mapped against the human genome, allowing 
identification of genetic variants present in the sequenced individual(s). 
Large databases of genetic variation (such as The HapMap project, UK10K, 1000genomes, Human 
Variome Project, and NCBI dbSNP) are used in interpreting sequence data obtained through MPS: 
identified variants can be characterized as part of the “normal” variability seen in the population, or as 
novel or rare variants and thus more likely to be pathogenic. Of note, population genetic variability 
differs among populations of different ethnicities; the sequence data of an individual should be compared 
against an ethnically-matched reference genome sequence. Once the sequence data have been generated 
and compared with the appropriate reference human genome, the data can be analyzed empirically based 
on the observed inheritance and population prevalence of the condition under examination. 
Although MPS was developed for whole-genome sequencing (WGS), targeted sequencing proved 
more cost-effective and efficient initially. Thus, prior to amplification, a library of fragments containing 
regions of particular interest may be selected (for example, by using probes that anneal to specific 
regions of interest, allowing their subsequent identification and isolation for PCR amplification and 
sequencing). Whole exome sequencing (WES) with capture and sequencing limited to gene exons may 
be particularly suited for rare Mendelian disorders since prior to the advent of MPS 85% of monogenic 
diseases were predicted to arise from protein-coding mutations [18]—whether this will hold true as more 
causative mutations are identified is as of yet unknown. 
The power of MPS methodology is illustrated by the many causative genetic mutations identified 
since its advent, especially since they are frequently mapped through sequencing of remarkably few 
individuals. Indeed, some disease genes have been identified through sequencing of a single proband [2], 
although confirmation of pathogenicity requires subsequent validation, such as genetic evidence in other 
affected individuals and/or functional studies of the candidate gene. 
4.2. Mapping Strategies for Monogenic Diseases Using MPS 
The experimental design for mapping a monogenic disease by WES does not necessarily require 
any prior linkage or association data. Rather it depends on the population frequency of disease, the 
mode of inheritance (including penetrance), and the presence or absence of consanguinity of the 
affected individuals. These parameters then determine an appropriately parsimonious experimental 
design—how many and which individuals should be sequenced and what empirical approach should 
be adopted for analysis of the sequence data. For example, a rare autosomal recessive condition in  
a non-consanguineous family is likely to arise from compound heterozygosity; identification of two 
novel (or very rare) damaging variants in a single gene provides strong evidence of likely causality 
even if only a single affected individual from the family is sequenced. In contrast, mapping an 
autosomal recessive condition in a consanguineous family is more difficult. In this circumstance, the 
disease is more likely to arise from homozygous carriage of a novel (or rare) variant carried by both 
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parents. However, a high number of homozygous rare variants would be expected due to consanguinity 
anyway; determining which of these is most likely pathogenic can be difficult. For an autosomal 
dominant condition, the most parsimonious experimental design is to sequence distantly-related 
affected individuals with a large number of meioses (and, by implication, recombination events) 
separating the affected cases—with n meioses between the individuals, the chance of a dominant 
variant segregating with affection status by chance is 1/2n. It is also possible to map de novo dominant 
conditions by sequencing unrelated individuals and analyzing the data either for a single variant carried 
by all affected individuals or for unique variants carried in a common gene by each individual [19]. 
These last analysis strategies depend crucially upon correct clinical phenotyping of the unrelated 
affected individuals. The inclusion of phenocopies in the analysis would decrease the success of 
mapping the causative gene—unless the stringent parameters of analysis are relaxed to allow for their 
possible presence. For example, one can search for a common shared gene amongst only a proportion 
of affected individuals rather than requiring a variant to be present in the same gene in every 
sequenced case. An alternative approach includes pathway analysis (searching for variants in a 
common pathway amongst individuals with a common phenotype). From a clinical viewpoint, large 
online databases cataloguing observed variants/mutations in patients with common conditions are also 
useful in identifying likely disease-causing mutation(s) (as examples, the Leiden Open Variation 
Database and the Genome Medicine Database of Japan). 
4.3. MPS Limitations 
Like all technologies, MPS has limitations. Good sequencing data depend upon sufficient capture of 
the causative gene by coverage of sufficient depth of sequencing to call homozygous or heterozygous 
variants (typically, 10-fold coverage is required for calling a homozygous variant and 15-fold  
for a heterozygous variant). WES off-the-shelf target platforms vary in their coverage of the “whole 
exome” [20,21], which may result in a gene of interest failing to be sequenced. For example, we (and 
others) failed to identify the disease-causing mutation in OI type V despite sequencing several families 
with the condition; the causative mutation was identified in the 5' UTR of IFITM5 [22,23], a region not 
captured with the whole exome capture platform we had employed. Less-than-complete whole exome 
capture can arise for several additional reasons, including new gene annotation subsequent to platform 
development and production [24]; a manufacturing decision to target only the main transcript for  
a gene rather than all known transcripts of a gene; and the technical challenges of capturing GC-rich 
sequences (which are common in the first exons of many genes [25]). Conversely, there are some 
regions that amplify excessively: if duplicates are not removed, strand-specific PCR-introduced errors 
may result, skewing variant allele frequencies with consequent effects on variant detection sensitivity 
and specificity [26]. Regions of genomic sequence similarity may result in non-specificity of target 
fragment selection—for example, a probe may anneal not only to the desired target exon but also to  
an unwanted region of high homology which, when incidentally captured and sequenced, results in 
apparently novel heterozygous variants at those points of difference between the two selected regions 
(a phenomenon known as multi-mapping [27]). 
However, despite these limitations, faced today with the challenge of identifying a rare gene 
mutation in a disease like FOP, WES of a small number of FOP patients would likely rapidly reveal 
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the recurrent c.617G>A (R206H) ACVR1 mutation, leading to quick recognition of ACVR1 as the 
disease-causing gene. If MPS technologies had been available when the search for the FOP gene 
began, the answer could have been found in 15 weeks, not 15 years. Certainly, this has proved to be 
the case in many other skeletal dysplasias where researchers are faced with similar issues of small 
families afflicted with diseases having a detrimental effect upon reproduction and lifespan [2,4]. 
4.4. Rare Variants as a Cause of Complex Diseases? 
Although we focused in this paper on the use of new mapping approaches for Mendelian disorders, 
MPS has also been used for mapping rare variants that contribute to the heritability of complex 
diseases. The contributions of rare variation in loci that also harbor common susceptibility alleles, or in 
genomic regions without common susceptibility alleles, are still the subject of active research. Whilst 
many examples exist of rare variants contributing to loci harboring common variant associations, these 
are few by comparison with the total number of common variant associations identified to date. Indeed, 
targeted sequencing of 25 loci associated with autoimmune disorders in nearly 25,000 individuals with six 
autoimmune phenotypes and just over 17,000 controls failed to identify any rare variants contributing 
significantly to immune-mediated disease susceptibility [28]. Styrkarsdottir et al. used whole genome 
scanning in the Icelandic population to identify a rare variant in LGR4 associated with both bone 
mineral density and fracture risk [29]. WES identified mutations in WNT1 as the cause of autosomal 
dominant early-onset osteoporosis in some families; however, as mutations in WNT1 were also identified 
in consanguineous families with autosomal recessive osteogenesis imperfecta it would perhaps be more 
correct to regard the families diagnosed with AD osteoporosis as having a subtle form of OI and/or  
a monogenic skeletal dysplasia rather than the common polygenic disease of osteoporosis [30,31]. 
Studies that conducted dense rare-variant genotyping, such as Immunochip-based analyses of  
immune-mediated diseases, have had little success in identifying novel rare variant associations, 
despite large sample sizes [29,32,33]. 
5. Conclusions and Challenges 
After mapping a disease-causing gene, many challenges remain, and many of these challenges are 
likely to be met through the resources and technologies that continue to build on the foundation of  
the Human Genome Project. 
One important consideration is in understanding the multiple genetic contributions to disease  
onset and progression in addition to the primary causative gene in monogenic disorders. In FOP,  
for example, although the main disease characteristics are unique and readily recognized, variability in 
the age of disease onset, the rate of disease progression, and the severity of disease can be high, even 
in the context of the same ACVR1 c.617G>A mutation. Such phenotypic variability is likely 
influenced by underlying genetic causes. Identification of genetic modifiers that “protect” an 
individual with an FOP mutation, for example by directing a late onset or less aggressive disease 
progression, would provide new therapeutic targets and strategies for treating the disease. Similar 
issues exist for many common heritable diseases, such as osteogenesis imperfecta and Marfan’s 
syndrome. With further development of genome technologies, the ability to understand phenotypic 
variability and the participation of genetic modifiers is becoming a reality. 
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The ultimate challenge is to elucidate the functions of the target gene and the consequences of its 
mutant forms, and, most importantly, the translation of this knowledge to treatments. Identification of 
the specific mutation in ACVR1 has clear and important diagnostic value, providing a means to 
confirm suspicion of FOP based on toe malformations or, in cases of potential inheritance (and when 
sequencing in early life becomes more commonplace), a means to diagnose the condition before 
irreversible clinical manifestations occur allowing for early intervention. Identification of the target 
pathway and the specific mutation mechanism in FOP has opened up therapeutic strategies for this 
disease. Additionally, although the roles of BMP signaling in a wide range of tissue development and 
homeostasis functions had been well established and the signaling pathway and its components were 
well defined prior to identifying the FOP mutation, the roles of ACVR1/ALK2 in these processes were 
unrecognized and poorly understood. FOP identified ACVR1 as a key regulator of skeletal development 
and bone formation, providing an important new focus for skeletal biology and regenerative medicine. 
This has been the case for many skeletal dysplasias mapped to date, in which the causative gene was 
often not known to be involved in bone prior to its identification [34]. There are many examples of 
such findings providing important insights into musculoskeletal development and pathology, and many 
current treatments have been developed based on genetic discoveries—for example the development of 
anti-sclerostin antibodies based on the discovery that the high bone mass conditions of sclerosteosis 
and van Buchem’s disease arise from mutations in the gene for sclerostin [35,36]. The power of MPS 
to map disease-associated mutations will thus benefit not only affected individuals and families,  
but also lead to a dramatic expansion in our understanding of human diseases. This will inform 
development of new therapies not only for rare monogenic disorders but also for diseases common in 
the general population. 
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